文献速递临床试验与 GCP流行病学与生物统计

ORVAC试验:澳大利亚原住民婴儿第三剂Rotarix轮状病毒疫苗的统计分析计划

The ORVAC trial: a phase IV, double-blind, randomised, placebo-controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis: a statistical analysis plan.
PubMed 文献 · Trials · 2020-08-26

ORVAC试验是一项IV期双盲随机安慰剂对照适应性设计,计划招募至多1000名6至<12月龄澳大利亚原住民婴儿,评估第三剂Rotarix轮状病毒疫苗能否提高对临床显著全因胃肠炎的保护。本文呈现贝叶斯适应性设计的统计分析计划,截至2020年8月已进行4次中期分析但未触发停止规则。

要点

  • 第三剂Rotarix用于6至<12月龄原住民婴儿,评估对全因胃肠炎的保护。
  • 共同主要终点为抗轮状病毒IgA血清阳转和至36月龄因急性胃肠炎就医时间。
  • 贝叶斯适应性设计已运行4次中期分析,未触发停止规则。

核心结论

  • 本文提出ORVAC试验的详细前瞻性统计分析计划,用于评估第三剂Rotarix对原住民婴儿胃肠炎保护效果。

研究设计与样本

  • IV期双盲随机安慰剂对照适应性设计,计划从北领地各地区招募至多1000名6至<12月龄原住民婴儿。
  • 统计分析计划由试验统计师撰写,详述研究设计、预设适应性要素、决策阈值、统计方法及评估试验操作特征的模拟。

主要发现

  • 截至2020年8月已运行4次中期分析,未触发停止规则。

关键数值与推荐

  • 共同主要终点1:Rotarix/安慰剂后28至55天血清抗轮状病毒IgA≥20 U/ml的血清阳转。
  • 共同主要终点2:随机化至36月龄前因急性胃肠炎或急性腹泻疾病就医的时间。
  • 次要终点包括抗轮状病毒IgA对数滴度变化、至36月龄前因急性腹泻住院时间、因轮状病毒确诊腹泻住院时间及轮状病毒感染时间。

临床怎么用

  • 该统计分析计划的应用将减少偏倚,支持透明和可重复的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this double-blind, randomised, placebo-controlled, adaptive design trial with frequent interim analyses is to determine if Australian Indigenous children, who receive an additional (third) dose of human rotavirus vaccine (Rotarix, GlaxoSmithKline) for children aged 6 to < 12 months, would improve protection against clinically significant all-cause gastroenteritis. PARTICIPANTS: Up to 1000 Australian Aboriginal and Torres Strait Islander (hereafter Indigenous) infants aged 6 to < 12 months will be recruited from all regions of the Northern Territory. INTERVENTIONS: The intervention is the addition of a third scheduled dose of human monovalent rotavirus vaccine. CO-PRIMARY AND SECONDARY OUTCOME MEASURES: ORVAC has two co-primary outcomes: (1) anti-rotavirus IgA seroconversion, defined as serum anti-rotavirus IgA ≥ 20 U/ml 28 to 55 days post Rotarix/placebo, and (2) time from randomisation to medical attendance for which the primary reason for presentation is acute gastroenteritis or acute diarrhoea illness before age 36 months. Secondary outcomes include (1) change in anti-rotavirus IgA log titre, (2) time from randomisation to hospitalisation with primary admission code presumed or confirmed acute diarrhoea illness before age 36 months, (3) time from randomisation to hospitalisation for which the admission is rotavirus confirmed diarrhoea illness before age 36 months and (4) time from randomisation to rotavirus infection (not necessarily requiring hospitalisation) meeting the jurisdictional definition before age 36 months. DISCUSSION: A detailed, prospective statistical analysis plan is presented for this Bayesian adaptive design. The plan was written by the trial statistician and details the study design, pre-specified adaptative elements, decision thresholds, statistical methods and the simulations used to evaluate the operating characteristics of the trial. As at August 2020, four interim analyses have been run, but no stopping rules have been triggered. Application of this SAP will minimise bias and supports transparent and reproducible research. TRIAL REGISTRATION: Clinicaltrials.gov NCT02941107. Registered on 21 October 2016 ORIGINAL PROTOCOL FOR THE STUDY: https://doi.org/10.1136/bmjopen-2019-032549.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jones MA, Graves T, Middleton B, et al. The ORVAC trial: a phase IV, double-blind, randomised, placebo-controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis: a statistical analysis plan. Trials. 2020. PMID: 32843086. doi:10.1186/s13063-020-04602-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。